Kukje Pharma

At a glance

Kukje Pharma filed 35 disclosures in the last 12 months, including 6 insider, 5 5% holder and 1 buyback. The most recent key filing was on Oct 8: CEO's holding rose by 1,815,237 sh (other change).

Revenue for 2025 was ₩175B, up 12.2% on 2024. Operating margin was 3.5% against 4.3% a year earlier. Debt was 87% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩92.3B and operating profit of ₩4.1B.

The 2025 annual report lists 272 employees with an average tenure of 12.4 years and average pay of ₩68.5M, #640 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩1.1B each on average. It paid ₩30 per common share in cash dividends, against ₩30 a year earlier (+0%). 남영우 and related parties held 37.87% at year end.

From the 2025 annual report

Staff: 272 (159 men, 113 women), of whom 28 on fixed-term contracts. Total pay for the year: ₩18.6B. Directors and auditors: 6, paid ₩6.4B in total.

Dividends (common shares)

Largest shareholder

남영우 holds 8.58%; with 9 related parties the group holds 37.87% of common shares at year end (from 37.86% at the start of the year).

Individuals paid ₩500M or more

Auditor: 대성회계법인 · opinion: Unqualified.

Rankings: Director pay #36 of 2,157

Source: 2025 annual business report (DART). How figures are combined

Financial summary